




**Supplementary Figure 1. Dose dependent LPS- and Poly (I:C) driven induction of preterm birth.**

(A-B) Gravid WT mice were challenged with increasing concentrations of LPS and of Poly (I:C) on d16 of gestation, and the incidence of PTB was quantified. Data represent percent of induction of term or PTB.




**Supplementary Figure 2. Impact of subclinical pathogen infection priming for secondary inflammatory challenge-driven IFN- $\alpha$  production.**

WT mice (n=3-6/condition) were mock-infected (saline) or infected with Influenza virus (PR8;  $6 \times 10^2$  PFU/mouse) or LCMV ( $5 \times 10^4$  PFU/mouse) for 24h or with *L. Monocytogenes* (Lm; WT,  $1 \times 10^2$  CFU) for 24h prior to being mock-challenged or challenged with LPS<sup>low</sup> for 4h and serum IFN- $\alpha$  levels were quantified by ELISA (PBL Interferon Source). ANOVA followed by Tukey's correction \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

**A****B**


**Supplementary Figure 3. Viral infection primes for secondary inflammatory challenge-driven cytokine production and induction of preterm birth in mice.**

(A-B) WT mice (n=3-6/condition) were mock-infected or infected as described above (Figure 1A) with Influenza virus or LCMV for 48h prior to being mock-challenged or challenged with LPS<sup>low</sup> for 4h and serum IFN-β, IL-6 and TNF levels were quantified by type I IFN activity assay and IVCCA respectively (actual values). ANOVA followed by Tukey's correction; \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. These data were used to calculate the % change of cytokine production over LPS<sup>low</sup> (shown in Figure 1).




**Supplementary Figure 4. Type I IFN/IFNAR axis is necessary for inflammatory challenge-driven cytokine production and induction of preterm birth in mice.**

(A) A schematic overview of tractable preclinical model of PTB induction employed to define the ability of viral mimetic in driving PTB. Gravid mice were challenged Poly (I:C)<sup>high</sup> on d16 of gestation, and the incidence of PTB was quantified. (B) WT mice (n=4-8/condition) were challenged with Poly (I:C) for 4h and IFN-β, IL-6 and TNF levels were quantified by type I IFN activity assay and IVCCA respectively. (A) Data represent percent of induction of term or PTB. (B) Dashed red line represents 100% induction of cytokine induction following Poly (I:C)<sup>low</sup> alone challenge in WT mice. Data represent percent change over LPS<sup>low</sup> (WT) + SE. (B) ANOVA followed by Tukey's correction; \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Supplementary Figure 5. Protection from LPS-driven PTB in mice lacking TLR4 and type I IFN signaling.**

(A) Gravid WT and KO mice were challenged LPS<sup>high</sup> on d16 of gestation, and the incidence of PTB was quantified. (B) WT and KO mice (n=3-4/condition) were challenged with LPS for 4h and IL-6 and TNF levels were quantified by IVCCA. Data represent percent change over LPS<sup>low</sup> (WT) + SE. (B) ANOVA followed by Tukey's correction; \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Supplementary Figure 6. Subclinical pathogen infection does not prime TLR4-deficient mice for secondary bacterial challenge proinflammatory cytokine production.**

WT and TLR4<sup>-/-</sup> mice (n=3-6/condition) were with Influenza virus or Lm for 48h or 24h prior to being mock-challenged or challenged with LPS<sup>low</sup> for 4h or Poly (I:C) alone (100 μg/mouse = low; 250 μg/mouse = high), or primed with Poly (I:C) for 4h prior to being challenged with LPS<sup>low</sup> and serum IL-6 levels were quantified by IVCCA. Data represent percent change over LPS<sup>low</sup> (WT) + SE. ANOVA followed by Tukey's correction \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Supplementary Figure 7. Physiological relevance of exogenous IFN-β levels utilized in our studies in comparison to subclinical pathogen infection.**

WT mice were challenged with recombinant mouse IFN-β (r IFN-β;  $10^4$  U/mouse) for 8 hr or infected with Influenza virus (PR8;  $6 \times 10^2$  PFU/mouse) or LCMV ( $5 \times 10^4$  PFU/mouse) for 48h or with *L. Monocytogenes* (Lm; WT,  $1 \times 10^2$  CFU) for 24h and serum IFN-β levels were quantified by ELISA. Data represent both as actual values and percent change over NS + SE as before. ANOVA followed by Tukey's correction \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Supplementary Figure 8. Transient IFN- $\beta$  priming effects on IL-6 production in vivo.**

WT mice (n=4-8/condition) were challenged with recombinant mouse IFN- $\beta$  ( $10^4$  U/mouse) for the indicated time points, LPS<sup>low</sup> or were primed with IFN- $\beta$  and challenged with LPS<sup>low</sup> and serum IL-6 levels were quantified by IVCCA. Dashed red line represents 100% induction of cytokine induction following LPS<sup>low</sup> alone challenge in WT mice. Data represent percent change over LPS<sup>low</sup> (WT) + SE. ANOVA followed by Tukey's correction \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.